Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J.M. Feingold
Interim Data From the First Clinical Study of Adct-301, a Novel Pyrrolobenzodiazapine-Based Antibody Drug Conjugate, in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group
Klinicka Onkologie
Oncology
Successful Rapid Desensitization to the Antibody–drug Conjugate Brentuximab Vedotin in a Patient With Refractory Hodgkin Lymphoma
Journal of Oncology Pharmacy Practice
Medicine
Oncology
Pharmacology
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim Analysis of Phase Iiib Magnify Study of Induction R2 Followed by Maintenance in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Treating Hodgkin Lymphoma in the New Millennium: Relapsed and Refractory Disease
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Novel Therapeutic Agents for Relapsed Classical Hodgkin Lymphoma
British Journal of Haematology
Hematology
Safety of Lisocabtagene Maraleucel Given With Durvalumab in Patients With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma: First Results From the Platform Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Annals of Hematology
Medicine
Hematology
